NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.
Germany's Curetis has initiated a prospective clinical trial in the European Union for its Unyvero molecular testing system and P50 Pneumonia test cartridge, the company said in February.
By Ben Butkus
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Curetis today announced its Series A financing round has increased by €9.6 million ($13.3 million) bringing the total amount raised in the round to €34.1 million.
According to founder and CEO Scott Tanner, the funds will go primarily toward ramping up production of CyTOF instruments, reagent production, and the establishment of a global sales and service team.
A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.
UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.
Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.
In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.